I.B. Beloglazova, Zh.A. Akopyan, M.N. Karagyaur, O.S. Plekhanova, E.V. Syomina, D.V. Stambolsky
Urokinase or plasminogen activator of urokinase-type belongs to the family of serine proteases. In addition to fibrinolysis, urokinase is involved in the regulation of processes such as inflammation, tissue remodeling during regeneration, angiogenesis, growth and metastasis of tumors. Such urokinase multifunctionality is caused by its ability to participate in the degradation of extracellular matrix, regulation of cell adhesion, migration and proliferation. Urokinase is involved in a number of processes itself alone, but in some of them it needs to interact with membrane receptors, adapter proteins, extracellular matrix proteins and other molecular partners. By stimulating of extracellular matrix proteolysis urokinase activats cell migration and proliferation, is involved in the pathogenesis of cancer. Blood vessels growth, the tumor feeding, the cancer cells division, their adhesion, migration and metastasis - processes in which urokinase is directly involved. Experimental studies on the suppression of the activity of urokinase and its interactions with protein partners have shown potential efficacy of inhibition of urokinase to suppress tumor growth. In this review, we discuss the perspectives of the creation drugs wich would target the urokinase system to inhibit tumor angiogenesis.